Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Earnings Recaps

IOVA Health Care 3 recaps
Q1 2026 May 8, 2026

Shares of Iovance Biotherapeutics declined 11.5% following the earnings release, reflecting investor disappointment primarily driven by cautious full-year guidance and signs of operational deceleration despite solid revenue growth.

Key takeaways
  • Q1 revenue grew approximately 45% year-over-year, driven by Amtagvi adoption.
  • Q2 revenue guidance of $86 million to $88 million implies a more modest sequential growth trajectory despite continued uptake.
  • Full-year 2026 revenue guidance was set at $350 million to $370 million, reflecting cautious outlook relative to implied peak sales potential.
  • Temporary manufacturing capacity reductions earlier in the quarter impacted production continuity, though in-house manufacturing is now fully resumed.
  • Margin improvement is expected over time from operational efficiencies, but no near-term margin expansion details were provided.
Full recap
Q3 2025 Nov 6, 2025

Iovance Biotherapeutics reported a solid Q3 2025, with a 13% revenue increase driven by Amtagvi sales and improved gross margins of 43%. The company is on track to meet its full-year revenue guidance of $250 million to $300 million.

Key takeaways
  • Q3 revenue reached approximately $68 million, led by Amtagvi sales of $58 million.
  • Gross margin improved significantly, from operational efficiencies and a 21% reduction in cost of sales.
  • Strong real-world evidence for Amtagvi shows a 60% response rate in the second-line melanoma treatment setting, enhancing its market position.
  • Iovance is advancing towards a supplemental biologics license application for non-squamous non-small cell lung cancer, with potential peak sales exceeding $1 billion in the U.S. alone.
  • Cash reserves of $307 million will support operations through the second quarter of 2027 as the company focuses on achieving profitability.
Full recap
Q2 2025 Aug 8, 2025

Iovance Biotherapeutics reported strong Q2 2025 performance with revenue of $60 million, driven by the successful rollout of Amtagvi, and announced a strategic restructuring to improve margins and operational efficiency.

Key takeaways
  • Revenue grew 22% sequentially to $60 million, with Amtagvi infusions contributing $54 million.
  • The company reaffirms 2025 revenue guidance of $250 million to $300 million, underpinned by strong demand for Amtagvi.
  • A strategic restructuring, including a 19% workforce reduction, is projected to yield over $100 million in annual cost savings starting Q4 2025.
  • Gross margin stood at 31%, with expectations for improvement through reduced costs of sales and enhanced manufacturing capacity utilization.
  • Strong real-world data indicates a nearly 49% response rate for Amtagvi, with plans to onboard large community practices in Q4 2025.
Full recap